Multiple Sclerosis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmac

Multiple Sclerosis Pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analyzes DelveInsight.

Multiple Sclerosis Overview:

Multiple sclerosis (MS) is the most prevalent neurological disorder among young adults, with symptoms typically emerging between ages 20 and 40. The disease targets axons in the central nervous system, which are shielded by myelin, also known as white matter.
The most common form, relapsing-remitting MS, affects approximately 85% of MS patients. It is characterized by episodes of symptom flare-ups (relapses or exacerbations) followed by periods of remission, during which symptoms improve or disappear. Some individuals with relapsing-remitting MS experience frequent symptoms that may be linked to specific triggers. Exacerbations, also referred to as relapses or recurrences, involve a sudden worsening of existing symptoms or the emergence of new ones that persist for at least 24 hours. These episodes are believed to result from the development of new lesions in the brain.
Early symptoms of MS often include:
Vision disturbances, such as blurred or double vision, or optic neuritis, which causes eye pain and rapid vision loss.
Muscle weakness, particularly in the hands and legs, along with muscle stiffness and painful spasms.
Tingling, numbness, or pain in the arms, legs, trunk, or face.
Clumsiness and difficulty maintaining balance while walking.
Bladder control issues.
Occasional or persistent dizziness.
There are also several rare and atypical forms of MS, each presenting with unique symptoms and progression patterns.

Request for a detailed insights report on Multiple Sclerosis pipeline insights @ https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Multiple Sclerosis Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Multiple Sclerosis Therapeutics Market.

Key Takeaways from the Multiple Sclerosis Pipeline Report

DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Sclerosis treatment.
In October 2024, Immunic, Inc. reported positive results from a non-binding interim futility analysis of its Phase III ENSURE trial, assessing its lead candidate, vidofludimus calcium (IMU-838), a nuclear receptor-related 1 (Nurr1) activator, for the treatment of relapsing multiple sclerosis (RMS).
That same month, Immunic, Inc. announced encouraging findings from the interim futility analysis of its Phase III ENSURE program, evaluating vidofludimus calcium (IMU-838) for RMS. Following the analysis, an Independent Data Monitoring Committee (IDMC) determined that the trials were not futile and recommended their continuation as planned.
In September 2024, Roche received FDA approval for an injectable version of its widely used multiple sclerosis treatment, Ocrevus. This new formulation shortens patient treatment time and enhances the company's competitive edge.
Also in September 2024, Sanofi shared results from its Phase III trials of tolebrutinib, an oral brain-penetrant BTK inhibitor for multiple sclerosis (MS). The HERCULES trial, which evaluated the drug's efficacy and safety in non-relapsing secondary progressive MS (nrSPMS), met its primary endpoint. However, the GEMINI 1 and GEMINI 2 trials did not achieve their objectives.
Key Multiple Sclerosis companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, and others are evaluating new drugs for Multiple Sclerosis to improve the treatment landscape.
Promising Multiple Sclerosis pipeline therapies in various stages of development include IMU-838, BIIB091, IMCY-0141, NeuroVax, and others.

Multiple Sclerosis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Multiple Sclerosis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Multiple Sclerosis market.

Download our free sample page report on Multiple Sclerosis pipeline insights @ https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple Sclerosis Emerging Drugs

IMU-838: Immunic Therapeutics
BIIB091: Biogen
IMCY-0141: ImCyse
NeuroVax: Immune Response BioPharma

Multiple Sclerosis Companies

Around 75 key companies are currently developing therapies for multiple sclerosis. Among them, Immunic Therapeutics has a drug candidate in the most advanced stage, Phase III.

DelveInsight's report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Multiple Sclerosis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Multiple Sclerosis Therapies and Key Companies: Multiple Sclerosis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Multiple Sclerosis Pipeline Therapeutic Assessment
• Multiple Sclerosis Assessment by Product Type
• Multiple Sclerosis By Stage
• Multiple Sclerosis Assessment by Route of Administration
• Multiple Sclerosis Assessment by Molecule Type

Download Multiple Sclerosis Sample report to know in detail about the Multiple Sclerosis treatment market @ Multiple Sclerosis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Multiple Sclerosis Current Treatment Patterns
4. Multiple Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Multiple Sclerosis Late-Stage Products (Phase-III)
7. Multiple Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Multiple Sclerosis Discontinued Products
13. Multiple Sclerosis Product Profiles
14. Multiple Sclerosis Key Companies
15. Multiple Sclerosis Key Products
16. Dormant and Discontinued Products
17. Multiple Sclerosis Unmet Needs
18. Multiple Sclerosis Future Perspectives
19. Multiple Sclerosis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Multiple Sclerosis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.